Article
Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes.
Cancer biology & therapy - 1 Nov 2005
Burger Herman, den Bakker Michael A, Kros Johan M, van Tol Hans, de Bruin Alex M, Oosterhuis Wolter, van den Ingh Harry F G M, van der Harst Erwin, de Schipper Hans P, Wiemer Erik A C, Nooter Kees
Abstract excerpt
Previous studies have shown that Imatinib mesylate (Gleevec), a selective tyrosine kinase inhibitor of c-KIT and platelet-derived growth factor receptors (PDGFR), is highly effective in c-KIT/CD117-positive gastrointestinal stromal tumors (GIST), especially in those having activating mutations in c-kit exon 11. In addition, gain-of-function mutations in the juxtamembrane domain (exon 12) and the kinase activation...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.